Nephros (NASDAQ:NEPH) Issues Earnings Results

Nephros (NASDAQ:NEPH) issued its quarterly earnings results on Thursday. The company reported $0.06 EPS for the quarter, Zacks reports. The company had revenue of $6.02 million for the quarter, compared to the consensus estimate of $4.99 million. Nephros had a return on equity of 11.03% and a net margin of 8.38%.

Here are the key takeaways from Nephros’ conference call:

• Record revenue and broad-based growth: Second-quarter revenue reached $6.0 million, up 36% year over year and 15% sequentially. Programmatic product revenue rose 27%, service revenue nearly tripled, and growth was driven largely by increased sales and services within existing customer sites.
• Profitability improved substantially: Net income increased more than 400% to approximately $1.2 million, while adjusted EBITDA rose 260% to $1.3 million. The company ended the quarter with $4.7 million in cash and no debt.
• Reported margins benefited from a one-time tariff refund: The 67% quarterly gross margin included approximately $600,000 of tariff refunds, about $500,000 of which related to inventory sold in prior periods. Management expects tariff policy, currency movements, shipping costs, and the growing mix of lower-margin services and commercial products to continue pressuring underlying margins.
• New products remain an emerging opportunity rather than a current growth driver: PFAS, microplastics, and nanoplastics offerings have not yet gained significant traction and may require additional education, trials, and regulatory momentum. Education initiatives are currently used to drive product adoption and are not being monetized directly.
• Cash generation weakened: Operating cash flow fell to $681,000 in the second quarter from $994,000 a year earlier, while first-half operations used $990,000 as accounts receivable and inventory increased.

Nephros Trading Up 17.3%

NEPH traded up $0.62 on Friday, hitting $4.21. 67,358 shares of the stock traded hands, compared to its average volume of 10,920. The business has a fifty day moving average price of $3.48 and a two-hundred day moving average price of $3.53. The firm has a market capitalization of $45.72 million, a PE ratio of 26.31 and a beta of 1.51. Nephros has a 52 week low of $2.66 and a 52 week high of $6.42.

Institutional Trading of Nephros

Several institutional investors have recently modified their holdings of the company. Topline Capital Management LLC lifted its holdings in shares of Nephros by 13.1% during the 2nd quarter. Topline Capital Management LLC now owns 477,449 shares of the company’s stock worth $1,953,000 after acquiring an additional 55,360 shares during the period. Quadrature Capital Ltd acquired a new stake in shares of Nephros during the 4th quarter valued at about $112,000. Marshall Wace LLP bought a new stake in Nephros in the fourth quarter valued at about $107,000. Renaissance Technologies LLC increased its stake in Nephros by 25.8% in the fourth quarter. Renaissance Technologies LLC now owns 103,772 shares of the company’s stock valued at $506,000 after acquiring an additional 21,272 shares during the period. Finally, Essex Investment Management Co. LLC raised its position in Nephros by 57.1% in the fourth quarter. Essex Investment Management Co. LLC now owns 38,984 shares of the company’s stock worth $190,000 after purchasing an additional 14,162 shares in the last quarter. Institutional investors and hedge funds own 41.10% of the company’s stock.

Analysts Set New Price Targets

NEPH has been the subject of several research reports. Zacks Research raised Nephros to a “hold” rating in a research report on Monday, July 20th. Northland Securities began coverage on shares of Nephros in a research report on Friday, July 17th. They set a “market perform” rating and a $4.00 target price on the stock. Finally, Weiss Ratings upgraded shares of Nephros from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 3rd. Three investment analysts have rated the stock with a Hold rating, According to data from MarketBeat, Nephros presently has a consensus rating of “Hold” and a consensus target price of $4.00.

About Nephros

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.